Capital World Investors Purchases New Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)

Capital World Investors bought a new position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 721,957 shares of the company's stock, valued at approximately $31,203,000. Capital World Investors owned 0.77% of Scholar Rock at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of SRRK. Barclays PLC grew its position in shares of Scholar Rock by 103.4% in the 3rd quarter. Barclays PLC now owns 165,449 shares of the company's stock valued at $1,324,000 after purchasing an additional 84,118 shares during the period. Geode Capital Management LLC grew its position in shares of Scholar Rock by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock valued at $12,361,000 after purchasing an additional 120,489 shares during the period. Exome Asset Management LLC acquired a new position in shares of Scholar Rock in the 3rd quarter valued at approximately $1,115,000. JPMorgan Chase & Co. grew its position in shares of Scholar Rock by 1.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock valued at $310,000 after purchasing an additional 379 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock valued at $34,000 after purchasing an additional 269 shares during the period. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Scholar Rock

In other news, Director Katie Peng sold 1,006 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total transaction of $34,626.52. Following the sale, the director now owns 30,319 shares in the company, valued at $1,043,579.98. This represents a 3.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Tracey Sacco sold 6,500 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $33.08, for a total value of $215,020.00. Following the sale, the insider now owns 71,750 shares in the company, valued at approximately $2,373,490. This represents a 8.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 250,231 shares of company stock worth $9,056,086. Corporate insiders own 13.30% of the company's stock.

Analyst Ratings Changes

Separately, Wedbush reiterated an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Scholar Rock currently has a consensus rating of "Buy" and a consensus price target of $42.67.

Scholar Rock Stock Down 4.6 %

NASDAQ SRRK traded down $1.57 during trading on Friday, hitting $32.81. The stock had a trading volume of 694,304 shares, compared to its average volume of 1,243,667. The company has a market capitalization of $3.11 billion, a PE ratio of -13.96 and a beta of 0.56. The company's 50-day moving average price is $32.77 and its two-hundred day moving average price is $35.72. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.